•
Dec 31, 2021
Scholar Rock Q4 2021 Earnings Report
Scholar Rock reported full year 2021 financial results and highlighted business progress.
Key Takeaways
Scholar Rock reported full year results, with a net loss of $131.8 million and revenue of $18.8 million. The company ended the year with approximately $253 million in cash, cash equivalents, and marketable securities.
Progressing Phase 3 SAPPHIRE clinical trial evaluating apitegromab in patients with non-ambulatory Type 2 and 3 Spinal Muscular Atrophy (SMA).
Two-year data from open label extension of TOPAZ Phase 2 trial in SMA expected by mid-2022.
Data from DRAGON Part B proof-of-concept trial evaluating SRK-181 to overcome checkpoint inhibitor resistance in cancer patients anticipated in 2022.
Ended 2021 with approximately $253 million in cash, cash equivalents, and marketable securities.